Form 4: Apellis Pharmaceuticals Acquired by Biogen

Apellis Pharmaceuticals has been acquired by Biogen in a merger transaction effective May 14, 2026.

Summary

• Apellis Pharmaceuticals, Inc. completed its merger with a subsidiary of Biogen Inc. on May 14, 2026.
• Shareholders received $41.00 per share in cash plus one contingent value right (CVR) per share.
• The CVR entitles holders to potential additional payments of up to $4.00 per share upon the achievement of specific milestones.
• All outstanding common stock, restricted stock units (RSUs), and qualifying stock options were converted into the right to receive the merger consideration or cancelled according to the merger agreement terms.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral-to-positive event for shareholders, as the acquisition provides immediate liquidity at a set price, though the ultimate value depends on the success of future milestones tied to the CVRs.

Positives

• Shareholders received a defined cash consideration of $41.00 per share.
• The inclusion of a CVR provides potential for additional upside of up to $4.00 per share based on future milestones.

Negatives

• Stock options with an exercise price equal to or greater than $45.00 were cancelled without any consideration.
• The company is no longer a publicly traded entity as it has become a wholly owned subsidiary of Biogen.

Risks

• The realization of the additional $4.00 per share CVR payment is contingent upon the achievement of specific, yet-to-be-met milestones.
• The CVRs are non-transferable, limiting liquidity for former shareholders regarding this portion of the consideration.

Future Outlook

The company has been acquired by Biogen and is now a wholly owned subsidiary; therefore, no independent future financial guidance is provided.

Management Comments

• The transaction was executed pursuant to the Agreement and Plan of Merger dated March 31, 2026.

Industry Context

StockSavvy.ai notes that this acquisition represents a significant consolidation in the biopharmaceutical sector, with Biogen expanding its portfolio through the absorption of Apellis Pharmaceuticals, a common trend in the industry where larger players acquire specialized biotech firms to bolster their pipelines.

Comparison to Industry Standards

• The use of CVRs in this acquisition is consistent with standard practices in biotech M&A, where future clinical or regulatory milestones are uncertain.
• The cash-out structure for vested options and RSUs aligns with typical change-of-control provisions found in similar pharmaceutical merger agreements.

Stakeholder Impact

• Shareholders have had their equity converted into cash and CVRs.
• Employees and management are now part of the Biogen organization.

Next Steps

• Achievement of milestones related to the CVR agreement.
• Distribution of potential CVR payments if milestones are met.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, Tender Offer, Contingent Value Right, CVR